Kiran Reddy, MD, MBA
Managing Director
Blackstone Life Sciences
Kiran Reddy, MD, MBA is President & CEO of Praxis Precision Medicines, Inc a biotech company focused on developing new therapies for neurologic and psychiatric disorders. Dr Reddy is a Venture Partner at Blackstone Life Sciences. He currently serves on the business advisory board of the National Epilepsy Foundation, the board of the New England Epilepsy Foundation and the Council for the National Center for Translational Sciences within NIH. Previously, Dr Reddy was at Biogen as part of the Corporate Strategy team where he focused on sourcing new technologies and product opportunities to support the Company’s growth via acquisitions, partnerships, and equity investments. Prior to Biogen, Dr Reddy was an Associate Partner at Third Rock Ventures. He supported and managed various portfolio companies in addition to focusing on new company formation and new investments. He was part of the founding team and Chief Business Officer for SAGE Therapeutics through its IPO. Dr Reddy was part of the team that launched Foundation Medicine, and was actively involved in the early investments into Alnara Therapeutics, Afferent Pharmaceuticals and Rhythm Pharmaceuticals. Dr Reddy holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard/Massachusetts General Hospital. He was previously a Howard Hughes science fellow, and has authored several peer-reviewed scientific papers in the field of epilepsy, neuroimmunology, and neurodegenerative diseases.
